CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 35 enrolled
Drug / intervention
e-Vapor Product A +3 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04881942
NCT04881942N/ACompleted

Characterization of Selected Aerosol Constituents Levels in the Exhaled Breath of Adult e-Vapor Users During Use of Four e-Vapor Products

Altria Client Services LLC·interventional·Posted May 11, 2021·Updated Jul 30, 2024

In Brief

A clinical study evaluating e-Vapor Product A, e-Vapor Product B, and 2 other interventions for Tobacco Use. Completed, enrolled 35 participants across 1 site.

Detailed Summary

This is an open-label, 4-way crossover study designed to estimate the nicotine, glycerin, propylene glycol, menthol, formaldehyde, acetaldehyde, and acrolein levels in exhaled breath samples during use of four MarkTen® XL e-vapor products. The study will enroll approximately 32 adult e-vapor-using subjects at one site in the United States in High Point, NC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTobacco Use
CountriesUnited States
CollaboratorsCato Research

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMay 11, 2021
Enrollment StartMar 27, 2017
Primary CompletionApr 21, 2017
Study CompletionJan 26, 2018
TodayJul 2, 2026
Enrollment to primary: 24 daysPosted 5.1 years ago

Interventions

e-Vapor Product Aother

e-Vapor product XL25F

e-Vapor Product Bother

e-Vapor product XL40CB

e-Vapor Product Cother

e-Vapor product XL35WM

e-Vapor Product Dother

e-Vapor product XL40MB